The Canadian government has given a startup the green light to export psychedelic substances to Australia for medicinal purposes. Optimi Health Corp. has been given the responsibility of transporting psilocybin-infused pills, derived from magic mushrooms, and MDMA, as approved by the health department.
The rising demand isn’t limited to the local magic mushrooms Ontario. Other countries are following Canada’s lead and starting to investigate and authorize the medicinal use of serotogenic compounds.
Confidently buy psychedelics online in Canada and discover your inherent potential through trustworthy sources.
[toc]Key Highlights:
- Vancouver-based startup Optimi Health has received a drug establishment license to send magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to utilize magic mushrooms in treating chronic depression.
- The treatment process includes three sessions over a span of five to eight weeks, with each session lasting approximately eight hours.
The Rise of Psilocybin Capsules in Canada
Vancouver-based Optimi plans to use its certification to broaden the pharmaceutical market for psychedelic drugs and gain an early foothold.
Seven firms have exported psilocybin, MDMA, or both, but exclusively for clinical research. A spokesperson from Canada’s health department could not confirm if these exports were for regular patient use and declined to name the companies due to privacy concerns.
This accomplishment places Optimi among a small group of international suppliers, with the current market trending more towards clinical rather than recreational use.
What’s in the Pill?
While the company hasn’t revealed the specific mushroom species used in the pill, they do work with various strains such as the Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, test, and extract its psychedelic mushrooms. This quaint town, home to approximately 3,000 people, is situated three hours east of Vancouver.
The Connection Between Australia and Psychedelic Mushrooms
It’s projected that one in five Australians, aged between 16 and 85, may face a mental health issue in their lifetime. PTSD (post-traumatic stress disorder) could potentially affect 11% of Australians, while anxiety disorders are common among 17% of the population.
There is a broad spectrum of mental health treatment methods, but not every method is effective for everyone. For patients unresponsive to certain treatments, finding a suitable alternative can be a difficult task, often leaving them more vulnerable.
Explanation of the Process
Australia has been at the forefront of using psilocybin, permitting licensed psychiatrists to employ this controlled substance in combating PTSD and depression that have shown resistance to traditional treatments.
In an unexpected decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic use. The TGA affirmed these substances are safe when used in a medically controlled environment for patients struggling with severe mental disorders.
This advancement has been a game-changer for numerous mental health professionals and researchers. The administration of these substances will be strictly monitored; it’s not as simple as just taking a pill and going on your way.
The typical treatment plan involves three sessions over a period of five to eight weeks. Each session lasts around eight hours, with the therapist remaining with the patient throughout the duration.
Canada’s Role in Psilocybin Research
Canada has come to the forefront as a significant center for psilocybin research, thereby greatly expanding our understanding of this compound. Health Canada, along with numerous institutions, is leading the charge in investigating the potential therapeutic uses of psilocybin for various mental health conditions.
Research institutions are no longer forced to classify these substances as illegal or rely on unauthorized dispensaries or mushroom stores. The government now authorizes certain institutions to grow mushrooms for research purposes.
The newfound availability of substances previously deemed harmful enables researchers to deepen their understanding of their potential benefits to many individuals.
A Recurring Trend
The potential of this field for addressing mental health conditions and substance abuse, including alcoholism, was first identified in the 1950s. Pioneers in this early research included English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer, who conducted their studies at the Saskatchewan Mental Hospital in Weyburn. Under the leadership of then-premier Tommy Douglas, significant advancements were made as the medical community was given considerable independence to explore their medical theories.
Dr. Osmond and Dr. Hoffer initiated studies using LSD, mescaline, and peyote as potential alternatives to the harsh methods of electroshock and lobotomy. Their research unfolded in unexpected ways, leading them to encourage doctors, nurses, and other healthcare staff to experiment with these substances.
Health Research Institutes of Canada
Through the Institute of Neurosciences, Mental Health and Addiction, the Health Research Institutes of Canada is funding three clinical trials to investigate the therapeutic efficiency and safety of psychotherapy assisted by psilocybin:
| Project Type | Study Focus | Research Institution | Main Investigator | Budget for the Project |
| A controlled trial with randomization | Psychological distress in end-stage cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms supporting psychotherapy with psilocybin for alcohol use disorder treatment | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A phase II clinical trial with randomization comparing single versus dual psychedelic doses | Depression resistant to treatment | University of Toronto | Joshua Rosenblat | $1,000,000 |
This financial support for research will enhance our understanding of the benefits of regulated substances. This initiative is part of the Canadian Drugs and Substances Strategy (CDSS) launched by the Government of Canada.
Further Research in Psychedelics
In Vancouver, psychiatrists have started a phase III clinical trial of MDMA, commonly known as ecstasy, for treating post-traumatic stress disorder (PTSD). The treatment protocol includes three eight-hour sessions with MDMA, scheduled a month apart, and nine 90-minute sessions without the drug. This trial is considered historically significant as it marks the first clinical evaluation of an illicit
This is the first psychedelic substance that has been studied in over four decades.
Getting to Know Psilocybin
Psilocybin, a naturally occurring psychedelic compound, is derived from certain types of mushrooms. When ingested, it transforms into psilocin, which in turn activates the serotonin 5-HT2a receptors found on the cortical pyramidal cells in the brain, the main hubs for processing.
The substance is currently being explored by local authorities for its potential to aid in the treatment of depression, anxiety, addiction, and end-of-life distress by promoting introspection and spiritual growth.
Why is it Potentially Effective for Depression, PTSD, and Other Conditions?
The active component of this substance influences several brain areas, making it potentially beneficial for a range of mental health conditions. Many patients in Canada and Australia have already undergone this therapy and the resulting feedback has been encouraging, with minor side effects such as temporary anxiety or increased blood pressure.
Neurobiological Effects
- Activation of Serotonin Receptors: This compound functions as a partial agonist at serotonin receptors, especially the 5-HT2A subtype, which is vital for emotional processing and the regulation of mood.
- Modulation of the Default Mode Network (DMN): The substance reduces activity in the DMN, promoting introspection, lessening rigid thinking patterns, and fostering emotional adaptability.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant properties of the compound are due to its effects on the prefrontal and limbic regions of the brain, including the amygdala. People suffering from depression often show decreased responsiveness to emotional stimuli. This substance increases the response to positive emotional stimuli in the right amygdala and normalizes the reaction to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Creation of Positive Mood States: Stimulates feelings of euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience could allow individuals to confront and process deep-seated emotions, traumatic memories, or existential concerns in a safe setting.
- Spiritual and Existential Insights: Studies from Johns Hopkins University and Imperial College Studies suggest that London’s approach can result in long-lasting positive changes such as enhanced well-being, increased life satisfaction, and spiritual growth.
What Can Be Found in Your Local Magic Mushroom Outlets?
Wondering how this substance might affect your mental health? Explore the local magic mushroom stores to locate a product that suits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, encourages creative thinking, and enhances productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Boosts wellness and enhances overall life satisfaction |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Encourages clarity, creativity, and focus. Contains a strong mixture of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy advantages |
Worldwide Acceptance of Psilocybin
Canada is not the only country supporting the utilization of magic mushrooms for mental health issues. Countries like Australia are also embracing these hallucinogens to treat disorders such as depression and PTSD. They are obtaining high-quality psychedelic capsules from trustworthy sources. With proper supervision, patients can significantly improve their life quality. Magic Mush Canada, a magic mushroom supplier, offers a variety of products, from pills to LSD edibles.
Frequently Asked Questions
What is the similarity between psilocybin and MDMA?
Both psilocybin and MDMA have potential therapeutic effects by enhancing mental wellness. Psilocybin interacts with serotonin 2A receptors and is effective in treating depression and addiction.
Conversely, MDMA promotes empathy and is beneficial in PTSD treatment. It shows promise in improving emotional processing and
This substance, though classified as controlled, has shown therapeutic potential.
Is this treatment accessible to all Australians?
Not exactly. In Australia, an individual’s eligibility to use this substance is determined following an evaluation. This assessment takes into account factors like existing heart ailments, a history of psychosis, etc. Only patients who haven’t found relief from traditional treatments for conditions such as depression, anxiety, or PTSD can access this treatment.
What are the implications of Canada’s mushroom exports?
Canada is positioning itself as a major player in the psychedelics market, mirroring its role in the cannabis industry. This could lead to an increase in the production of high-quality products by more companies. As a result, Canada could potentially become a leader in the hallucinogen market, strengthening its economy and providing access to treatments for other nations. This would also discourage countries from procuring their hallucinogens from illegitimate sources, thereby ensuring safety.
Related Articles You Might Find Interesting:
